New U.S. guidance carves out tariff exemptions for specialty pharmaceuticals, Pharming's Fabrice Chouraqui steps down as CEO ...

Pharming CEO Fabrice Chouraqui has stepped down amid strategic disagreements with the board, with chief commercial officer Leverne Marsh and chief financial officer Kenneth Lynard now serving as ...

New U.S. guidance exempts orphan drugs, nuclear medicines, cell and gene therapies, and other specialty products from the 100% pharmaceutical tariff when imported from 19 named countries.

Two global partnerships surfaced across metabolic disease and oncology this week, as Novo and AstraZeneca each moved to expand their pipelines through deals with clinical-stage in ...

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

Two FDA approvals, six platform deals, a European alarm, a Novo listing debate, and a China mega-deal — this week's biggest ...

Merck has acquired exclusive global rights to SciBrunch's preclinical KRAS G12D inhibitor SPR2015. Merck entered into an ...

Pharmaceutical Executive spoke with Michael Abrams, managing partner at global healthcare consultancy Numerof & Associates ...

Compounding pharmacies that set their own safety and accreditation standards now stand the best chance of keeping patient ...

Incyte received a Rare Pediatric Disease Priority Review Voucher tied to zilurgisertib’s FOP approval, while Mirum plans U.S.

FDA authorization is underpinned by four global Phase III QWINT studies showing non-inferior A1C lowering versus glargine ...

New U.S. guidance carves out tariff exemptions for specialty pharmaceuticals, Pharming's Fabrice Chouraqui steps down as CEO amid a board rift, and a dealmaking roundup covers Hengrui Pharma's ...